Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in Humana Inc. (NYSE:HUM)

Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Humana Inc. (NYSE:HUM) by 9.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 188,793 shares of the insurance provider’s stock after purchasing an additional 16,089 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Humana were worth $49,552,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the fourth quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new stake in Humana in the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA lifted its stake in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Humana during the 4th quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. grew its position in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

NYSE:HUM opened at $263.95 on Friday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $31.86 billion, a PE ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The business’s fifty day moving average price is $270.14 and its 200 day moving average price is $274.38.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. Humana’s dividend payout ratio is presently 35.58%.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.37% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on HUM shares. JPMorgan Chase & Co. lowered their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Barclays raised their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, Piper Sandler lifted their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Eighteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.